Head-To-Head Analysis: Akers Biosciences (AKER) & Riot Blockchain (RIOT)

Akers Biosciences (NASDAQ:AKER) and Riot Blockchain (NASDAQ:RIOT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Risk and Volatility

Akers Biosciences has a beta of -1.63, suggesting that its share price is 263% less volatile than the S&P 500. Comparatively, Riot Blockchain has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Akers Biosciences and Riot Blockchain, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences 0 0 0 0 N/A
Riot Blockchain 0 0 1 0 3.00

Riot Blockchain has a consensus target price of $4.00, indicating a potential upside of 131.21%. Given Riot Blockchain’s higher possible upside, analysts plainly believe Riot Blockchain is more favorable than Akers Biosciences.

Earnings & Valuation

This table compares Akers Biosciences and Riot Blockchain’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akers Biosciences $3.93 million 4.35 -$7.36 million N/A N/A
Riot Blockchain $170,000.00 147.56 -$19.84 million ($2.71) -0.64

Akers Biosciences has higher revenue and earnings than Riot Blockchain.

Profitability

This table compares Akers Biosciences and Riot Blockchain’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akers Biosciences -346.69% -107.79% -85.96%
Riot Blockchain -883.37% -92.58% -67.12%

Institutional and Insider Ownership

50.6% of Akers Biosciences shares are owned by institutional investors. Comparatively, 8.9% of Riot Blockchain shares are owned by institutional investors. 8.9% of Akers Biosciences shares are owned by company insiders. Comparatively, 2.7% of Riot Blockchain shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Riot Blockchain beats Akers Biosciences on 6 of the 11 factors compared between the two stocks.

About Akers Biosciences

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ‘Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

About Riot Blockchain

Riot Blockchain, Inc. focuses on building, supporting, and operating blockchain technologies, primarily through its cryptocurrency mining operations and other developed businesses, as well as joint ventures, acquisitions, and targeted investments in the sector. Its primary focus is on Bitcoin and general blockchain technology. The company leverages its expertise and network to build and support blockchain technology companies. It builds a cryptocurrency mining operation and operates specialized computers that generate cryptocurrency, primarily Bitcoin. The company also holds interests in various activities, including purchasing and selling cryptocurrencies; providing accounting, audit, and verification services for blockchain based assets, such as cryptocurrencies; and developing TessPay, a payments ecosystem for component and sub-component supply chain settlements, and other blockchain solutions for telecommunications companies. As of March 31, 2018, approximately 3,500 of the miners were installed and operating. The company was formerly known as Bioptix, Inc. and changed its name to Riot Blockchain, Inc. in October 2017. Riot Blockchain, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply